LivaNova PLC (NASDAQ:LIVN) insider David S. Wise sold 1,500 shares of LivaNova stock in a transaction on Thursday, March 15th. The shares were sold at an average price of $88.17, for a total value of $132,255.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.
LIVN traded up $0.18 on Thursday, hitting $85.96. 227,514 shares of the company were exchanged, compared to its average volume of 403,786. LivaNova PLC has a twelve month low of $49.68 and a twelve month high of $92.31. The stock has a market capitalization of $4,155.89, a price-to-earnings ratio of 24.38, a PEG ratio of 2.69 and a beta of 0.75. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.14 and a quick ratio of 1.79.
LivaNova (NASDAQ:LIVN) last released its earnings results on Wednesday, February 28th. The company reported $0.88 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.78 by $0.10. LivaNova had a positive return on equity of 9.37% and a negative net margin of 2.10%. The firm had revenue of $278.40 million during the quarter, compared to analysts’ expectations of $278.48 million. During the same period in the previous year, the firm posted $0.83 EPS. LivaNova’s revenue for the quarter was up 11.5% on a year-over-year basis. research analysts anticipate that LivaNova PLC will post 3.2 earnings per share for the current year.
A number of equities research analysts have recently weighed in on LIVN shares. ValuEngine cut LivaNova from a “buy” rating to a “hold” rating in a research note on Wednesday, December 20th. Zacks Investment Research cut LivaNova from a “hold” rating to a “strong sell” rating in a research note on Thursday, January 25th. BidaskClub cut LivaNova from a “buy” rating to a “hold” rating in a research note on Thursday, January 18th. Canaccord Genuity lifted their price objective on LivaNova from $76.00 to $81.00 and gave the company a “hold” rating in a research note on Tuesday, February 27th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $104.00 price objective (up from $97.00) on shares of LivaNova in a research note on Wednesday, February 28th. One research analyst has rated the stock with a sell rating, three have given a hold rating and six have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $81.43.
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Parametric Portfolio Associates LLC lifted its holdings in LivaNova by 106.8% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 15,042 shares of the company’s stock worth $921,000 after buying an additional 7,769 shares during the last quarter. Aperio Group LLC purchased a new stake in LivaNova during the 3rd quarter worth about $393,000. Crossmark Global Holdings Inc. purchased a new stake in LivaNova during the 3rd quarter worth about $263,000. Principal Financial Group Inc. lifted its holdings in LivaNova by 1.3% during the 3rd quarter. Principal Financial Group Inc. now owns 186,705 shares of the company’s stock worth $13,081,000 after buying an additional 2,433 shares during the last quarter. Finally, Sei Investments Co. purchased a new stake in LivaNova during the 3rd quarter worth about $1,093,000. 85.51% of the stock is owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY WARNING: This news story was reported by Macon Daily and is the sole property of of Macon Daily. If you are viewing this news story on another site, it was illegally copied and reposted in violation of U.S. and international trademark and copyright legislation. The correct version of this news story can be accessed at https://macondaily.com/2018/04/12/david-s-wise-sells-1500-shares-of-livanova-plc-livn-stock-updated-updated-updated.html.
LivaNova PLC is a medical device company focused on the development and delivery of therapeutic solutions. The Company’s segments include Cardiac Surgery, Cardiac Rhythm Management, Neuromodulation and Other. The Cardiac Surgery segment is engaged in the development, production and sale of cardiovascular surgery products.
Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.